Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Capital Expenditures (2019 - 2026)

Immunovant filings provide 7 years of Capital Expenditures readings, the most recent being $201000.0 for Q1 2025.

  • Quarterly Capital Expenditures rose 34.0% to $201000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $201000.0 through Dec 2025, down 71.61% year-over-year, with the annual reading at $759000.0 for FY2025, 110.83% up from the prior year.
  • Capital Expenditures hit $201000.0 in Q1 2025 for Immunovant, up from $180000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $201000.0 in Q1 2025 and bottomed at $18000.0 in Q2 2021.
  • Average Capital Expenditures over 5 years is $97941.2, with a median of $95000.0 recorded in 2021.
  • The largest annual shift saw Capital Expenditures surged 850.0% in 2021 before it plummeted 77.97% in 2023.
  • Immunovant's Capital Expenditures stood at $74000.0 in 2021, then soared by 32.43% to $98000.0 in 2022, then skyrocketed by 33.67% to $131000.0 in 2023, then soared by 37.4% to $180000.0 in 2024, then increased by 11.67% to $201000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Capital Expenditures are $201000.0 (Q1 2025), $180000.0 (Q4 2024), and $196000.0 (Q3 2024).